HAVCR2 and lung carcinoma: demonstrate that BTLA, along with markers like PD-1 and TIM-3, is upregulated in T cells post-tumor implantation in mice and in infiltrating CD8 T cells in advanced lung cancer patients, underscoring its role in T cell dysfunction during tumor progression (57, 58).